To date, the U.S. Food and Drug Administration (FDA) has approved three selective CDK inhibitors (palbociclib, ribociclib, and abemaciclib) for breast cancer, and 15 CDK4/6 inhibitors are in clinical trials [42]. Here, CDK4 is linked to breast cancer.